- Home
- TGTX vs VERX Comparison
TGTX vs VERX Comparison
Compare TGTX & VERX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- VERX
- Stock Information
- Founded
- TGTX 1993
- VERX 1978
- Country
- TGTX United States
- VERX United States
- Employees
- TGTX N/A
- VERX N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- VERX Computer Software: Prepackaged Software
- Sector
- TGTX Health Care
- VERX Technology
- Exchange
- TGTX Nasdaq
- VERX Nasdaq
- Market Cap
- TGTX 4.2B
- VERX 4.1B
- IPO Year
- TGTX 1995
- VERX 2020
- Fundamental
- Price
- TGTX $32.18
- VERX $24.03
- Analyst Decision
- TGTX Strong Buy
- VERX Buy
- Analyst Count
- TGTX 4
- VERX 13
- Target Price
- TGTX $42.50
- VERX $42.83
- AVG Volume (30 Days)
- TGTX 2.0M
- VERX 1.4M
- Earning Date
- TGTX 11-03-2025
- VERX 11-05-2025
- Dividend Yield
- TGTX N/A
- VERX N/A
- EPS Growth
- TGTX N/A
- VERX N/A
- EPS
- TGTX 0.36
- VERX N/A
- Revenue
- TGTX $454,069,000.00
- VERX $710,512,000.00
- Revenue This Year
- TGTX $82.58
- VERX $15.19
- Revenue Next Year
- TGTX $44.99
- VERX $13.21
- P/E Ratio
- TGTX $89.78
- VERX N/A
- Revenue Growth
- TGTX 30.96
- VERX 15.00
- 52 Week Low
- TGTX $21.16
- VERX $23.13
- 52 Week High
- TGTX $46.48
- VERX $60.71
- Technical
- Relative Strength Index (RSI)
- TGTX 57.80
- VERX 36.47
- Support Level
- TGTX $31.34
- VERX $23.70
- Resistance Level
- TGTX $32.57
- VERX $25.96
- Average True Range (ATR)
- TGTX 1.13
- VERX 0.99
- MACD
- TGTX 0.54
- VERX 0.23
- Stochastic Oscillator
- TGTX 76.10
- VERX 26.26
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About VERX Vertex Inc.
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.